Targeting chemokines and chemokine receptors with antibodies
Copyright policy )Targeting chemokines and chemokine receptors with antibodies
Chemokines and their receptors are highly interesting therapeutic targets for pharmaceutical and biotechnology companies. In particular, industrial development pipelines are filled with new chemokine-targeting drugs to treat inflammatory diseases and malignancies. In this review, we specifically highlight antibody-based therapeutics and monoclonal antibodies (mAbs) targeting the chemokine system. Besides discussing pitfalls inherently linked to their discovery, we will elaborate on where progress can be made in the development of novel human therapeutic antibodies directed at the chemokine system. © 2012 Elsevier Ltd. All rights reserved.
- Utrecht University Netherlands
- Vrije Universiteit Amsterdam Netherlands
- Chemistry and Pharmaceutical Sciences, Medicinal chemistry Netherlands
- University of Amsterdam Netherlands
SDG 17 - Partnerships for the Goals, SDG 3 - Good Health and Well-being
SDG 17 - Partnerships for the Goals, SDG 3 - Good Health and Well-being
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).29 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!